Lorenzo Calvetti

Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors

Alberto Pavan, Lorenzo Calvetti, Alessandro Dal Maso et al. · The Oncologist · 2019 · 224 citations

Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study

Alessandro Russo, Marco Russano, Tindara Franchina et al. · Advances in Therapy · 2020 · 165 citations

Medicine, Immunology, Hematology +9

A validated prognostic classifier for BRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Fotios Loupakis, Rossana Intini, Chiara Cremolini et al. · European Journal of Cancer · 2019 · 69 citations · Full text

Prognostic Biomarkers, Gastrointestinal Oncology, Medicine +7

Clinico-pathological nomogram for predicting BRAF mutational status of metastatic colorectal cancer

Fotios Loupakis, Roberto Moretto, Giuseppe Aprile et al. · British Journal of Cancer · 2015 · 59 citations · Full text

Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome

Alberto Pavan, Andrea Boscolo Bragadin, Lorenzo Calvetti et al. · Translational Lung Cancer Research · 2021 · 43 citations · Full text